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BACKGROUND
Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of 
treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was supe-
rior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We 
report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 
12-week and 60-week data from a third phase 3 trial, UNCOVER-1.
METHODS
We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the 
UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous 
injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a 
starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks 
after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the 
UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of 
etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a 
long-term extension period during which they received 80 mg of ixekizumab every 
4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, 
the patients who had a response to ixekizumab (defined as a static Physicians Global 
Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reas-
signed to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixeki-
zumab every 12 weeks through week 60. Coprimary end points were the percentage 
of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction 
from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12.
RESULTS
In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab 
than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 
89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 
76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 
for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 
trials, among the patients who were randomly reassigned at week 12 to receive 80 mg 
of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an 
sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, re-
spectively. Patients in the UNCOVER-3 trial received continuous treatment of ixeki-
zumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 
0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixeki-
zumab use included neutropenia, candidal infections, and inflammatory bowel disease.
CONCLUSIONS
In three phase 3 trials involving patients with psoriasis, ixekizumab was effective 
through 60 weeks of treatment. As with any treatment, the benefits need to be 
weighed against the risks of adverse events. The efficacy and safety of ixekizumab 
beyond 60 weeks of treatment are not yet known. (Funded by Eli Lilly; UNCOVER-1, 
UNCOVER-2, and UNCOVER-3 ClinicalTrials.gov numbers NCT01474512, NCT01597245, 
and NCT01646177, respectively.)
A BS TR AC T
Phase 3 Trials of Ixekizumab 
in Moderate-to-Severe Plaque Psoriasis
K.B. Gordon, A. Blauvelt, K.A. Papp, R.G. Langley, T. Luger, M. Ohtsuki, K. Reich, 
D. Amato, S.G. Ball, D.K. Braun, G.S. Cameron, J. Erickson, R.J. Konrad, T.M. Muram, 
B.J. Nickoloff, O.O. Osuntokun, R.J. Secrest, F. Zhao, L. Mallbris, and C.L. Leonardi, 
for the UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups* 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF PISA on October 23, 2018. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;4 nejm.org July 28, 2016346
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Psoriasis is a chronic inflammatory disease that is mediated by aberrant im-mune responses and driven by self-perpet-
uating cytokine networks.1,2 Advances in under-
standing the pathogenic cytokine network of 
psoriasis have led to the development of new 
treatments3-5 that provide greater efficacy in 
terms of complete skin clearance.6-9 The motiva-
tion to completely clear psoriasis plaques from 
the skin of patients has grown in response to 
accumulating evidence that residual skin disease 
can affect a patient’s health-related quality of 
life10-12 similar to that associated with chronic 
conditions such as type 2 diabetes.13
Ixekizumab, a recombinant, high-affinity, hu-
manized, IgG4-κ monoclonal antibody, selectively 
binds and neutralizes interleukin 17A (IL-17A), 
the proinflammatory and primary effector cy-
tokine of type 17 helper T (Th17) cells.5 The 
UNCOVER-2 and UNCOVER-3 trials showed that 
after a 12-week induction period, ixekizumab 
was superior to placebo and to twice-weekly 
etanercept for the treatment of moderate-to-
severe psoriasis.9 Here we report the 12-week 
efficacy data from the UNCOVER-1 trial, the 
maintenance of response up to week 60 in all 
three UNCOVER trials, and the integrated safety 
data from the cumulative UNCOVER data set that 
included data from 3736 patients, representing 
3458 patient-years of exposure to ixekizumab.
Me thods
Trial Oversight
The trials were sponsored by Eli Lilly and were 
designed by the scientific steering committee 
and Eli Lilly personnel. The site investigators 
collected the data, Eli Lilly personnel performed 
the data analyses, and all the authors had access 
to the data. All the authors take responsibility 
for the accuracy and completeness of the reported 
data and analyses for the trials in which they 
were involved and vouch for the fidelity of the 
trials to the protocols, available with the full text 
of this article at NEJM.org. The agreements be-
tween Eli Lilly and the investigators included 
provisions relating to confidentiality of the trial 
data. The initial draft of the manuscript was 
written by a medical writer paid by Eli Lilly, 
and subsequent revisions were made by all the 
authors. A second medical writer paid by Eli 
Lilly provided writing support during the review 
of the manuscript. The trial protocols were ap-
proved by the institutional review board or ethics 
committee at each participating site, and the tri-
als were conducted in accordance with the ethical 
principles of the Declaration of Helsinki. Eligible 
patients provided written informed consent.
Trial Population
The eligibility criteria were similar for all three 
trials. Eligible patients were 18 years of age or 
older; had moderate-to-severe plaque psoriasis 
that had been diagnosed at least 6 months before 
randomization; and were candidates for photo-
therapy, systemic therapy, or both, with 10% or 
more of their body-surface area affected by pso-
riasis, a static Physician’s Global Assessment 
(sPGA) score of 3 or higher (on a scale of 0 to 5, 
with higher scores indicating more severe dis-
ease),14 and a Psoriasis Area and Severity Index 
(PASI) of 12 or higher (on a scale from 0 to 72, 
with higher scores indicating more severe dis-
ease)14 at both the screening and baseline visits.
Patients were excluded if they had forms of 
psoriasis other than chronic plaque psoriasis 
(such as drug-induced psoriasis or guttate, eryth-
rodermic, or pustular psoriasis) or if the psoria-
sis did not meet the criterion of chronicity as de-
fined by the investigator (i.e., the patient had had 
a clinically significant f lare of psoriasis within 
12 weeks before baseline). The use of medications 
that might confound efficacy was not allowed. 
In the UNCOVER-2 and UNCOVER-3 trials, pa-
tients who had used etanercept at any time 
before screening were excluded. (Details of the 
prohibited medications and exclusion criteria, as 
well as the treatments permitted during the trials, 
are provided in the Methods section in the Sup-
plementary Appendix, available at NEJM.org.)
Trial Design
Overview
The trials were multicenter, randomized, dou-
ble-blind, placebo-controlled phase 3 trials; an 
active drug control was also included in the 
UNCOVER-2 and UNCOVER-3 trials. Overall, the 
trials were conducted at 100 sites worldwide. A 
list of the participating sites and the patient flow 
charts for each of the three UNCOVER trials are 
provided in Table S1 and Figures S1, S2, and S3 
in the Supplementary Appendix.
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Induction Period (UNCOVER-1)
During the induction period in the UNCOVER-1 
trial, the patients were randomly assigned, in a 
1:1:1 ratio, to receive subcutaneous injections of 
placebo (placebo group), 80 mg of ixekizumab 
every 2 weeks after a starting dose of 160 mg at 
week 0 (2-wk dosing group), or 80 mg of ixekizu-
mab every 4 weeks after a starting dose of 160 mg 
at week 0 (4-wk dosing group). For all trials and 
trial periods, placebo was given to match all 
active treatment dosing regimens. The placebo 
group comprised 431 patients, the 2-wk dosing 
group 433 patients, and the 4-wk dosing group 
432 patients. The designs of the induction peri-
ods in the UNCOVER-2 and UNCOVER-3 trials 
were published previously.9
Long-Term Extension Period (UNCOVER-3)
In the UNCOVER-3 trial, the patients who com-
pleted the 12-week induction period entered the 
long-term extension period at the discretion of 
the investigator and the patient. All patients re-
ceived ixekizumab every 4 weeks; the patients 
who had received placebo during the 12-week in-
duction period received a starting dose of 160 mg 
of ixekizumab at week 12, followed by 80 mg 
every 4 weeks, and the patients who had received 
etanercept during the induction period had a 
4-week washout period before receiving 80 mg 
of ixekizumab every 4 weeks starting at week 16.
Randomized Withdrawal Period (UNCOVER-1  
and UNCOVER-2)
The UNCOVER-1 and UNCOVER-29 trials had 
similar induction designs. At week 12, the pa-
tients who received ixekizumab were classified 
as either having had a response (defined as an 
sPGA score of 0 [clear] or 1 [minimal psoriasis]) 
or not having had a response (defined as an 
sPGA score >1). Patients who had had a response 
entered a randomized withdrawal period (weeks 
12 through 60) in which they were randomly 
reassigned (stratified according to ixekizumab-
regimen group during the induction period), in 
a 1:1:1 ratio, to receive subcutaneous injections 
of placebo (402 patients), 80 mg of ixekizumab 
every 4 weeks (416 patients), or 80 mg of ixeki-
zumab every 12 weeks (408 patients). Patients 
who had an sPGA score of 3 or higher (indicating 
relapse in the trials) during weeks 12 through 60 
were classified as not having a response at all 
later time points; among these patients, those 
who were already receiving the every-4-week 
regimen maintained that regimen and those 
who were receiving the every-12-week regimen 
or placebo were switched to the every-4-week 
regimen.
End Points and Assessments
The primary objective in the UNCOVER-1 trial 
was to assess whether ixekizumab would be su-
perior to placebo with respect to the coprimary 
efficacy end points of a 75% or greater reduction 
from baseline in PASI (PASI 75) and an sPGA 
score of 0 (clear) or 1 (minimal psoriasis) at 
week 12.14 Secondary objectives were to assess 
whether ixekizumab would be superior to pla-
cebo with respect to the major secondary effi-
cacy end points of a 90% or greater reduction 
from baseline in PASI (PASI 90) and complete 
resolution of psoriasis plaques (sPGA score of 
0 and a 100% reduction from baseline in PASI 
[PASI 100]). The objectives in the UNCOVER-2 
and UNCOVER-3 trials at week 12 have been 
published previously.9 Major secondary efficacy 
end points for the randomized withdrawal peri-
ods in the UNCOVER-1 and UNCOVER-2 trials 
included the percentage of patients who main-
tained an sPGA score of 0 or 1 at week 60. The 
sPGA and PASI end points in the long-term ex-
tension period in the UNCOVER-3 trial were re-
ported through week 60 (details of the end-point 
assessments are provided in the Supplementary 
Appendix.)
We evaluated safety by monitoring adverse 
events, including the severity of the event and 
the relationship of the event to the use of the 
study drug or placebo, and by obtaining clinical 
laboratory measurements through 60 weeks. An 
independent, external cardiovascular and cere-
brovascular safety adjudication committee was 
established to review and adjudicate major ad-
verse cardiovascular or cerebrovascular events, 
which were reported in a blinded manner. Ad-
verse events that occurred during the treatment 
periods, which included the induction period 
(weeks 0 to 12), the maintenance period (weeks 
12 through 60), and the combined period (weeks 
0 through 60), were defined as those that ap-
peared or worsened during the period from im-
mediately after the first injection through the 
date of the last visit in that treatment period. 
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Adverse events of special interest included seri-
ous infections, candidal infections, neutrope-
nia, inflammatory bowel disease, cardiovascu-
lar or cerebrovascular events and major adverse 
cardiovascular or cerebrovascular events, and 
cancer.
Statistical Analysis
Unless otherwise specified, all analyses of effi-
cacy during the induction period were per-
formed according to the intention-to-treat prin-
ciple. Missing values for the PASI and the sPGA 
score were imputed conservatively as nonre-
sponses, regardless of the reason for the miss-
ing data. In the primary-analysis population, 
comparisons of efficacy among the study groups 
with respect to categorical variables during the 
induction period were performed with the use of 
logistic-regression analysis. Secondary analyses 
of efficacy with respect to categorical variables 
were performed with the use of Fisher’s exact 
test. A gatekeeping testing strategy for primary 
and major secondary analyses was implemented 
to control the overall type I error rate at a two-
sided alpha level of 0.05. The gatekeeping proce-
dure was based on the Bonferroni test and used 
an intuitive, stepwise testing algorithm. The al-
pha levels for the P values associated with the 
results of the primary and secondary analyses 
were computed at each step, depending on the 
results of the preceding tests of significance. 
(The order in which the primary and major sec-
ondary objectives were tested, along with addi-
tional details of the statistical analysis, is pro-
vided in the Supplementary Appendix.)
The analyses of efficacy during the random-
ized withdrawal periods were performed with 
the use of integrated data from the UNCOVER-1 
and UNCOVER-2 trials. Comparisons of efficacy 
among the study groups with respect to categor-
ical variables were performed with the use of the 
Cochran–Mantel–Haenszel test, stratified accord-
ing to trial. In the long-term extension period in 
the UNCOVER-3 trial, efficacy was summarized 
by descriptive statistics.
Safety analyses included all patients who re-
ceived at least one dose of the study drug or pla-
cebo. The rates of adverse events were compared 
among the study groups and analyzed with the 
use of the Cochran–Mantel–Haenszel test, strat-
ified according to trial. Exposure-adjusted inci-
dence rates were calculated for common adverse 
events and serious adverse events that occurred 
during each treatment period (the induction pe-
riod, the maintenance period, and the combined 
period); exposure-adjusted incidence rates were 
calculated as the total number of patients who 
had an adverse event or serious adverse event 
during each treatment period, divided by the 
total of all patients’ exposure during the same 
treatment period (per 100 patient-years). A Pois-
son regression model was used to analyze expo-
sure-adjusted incidence rates.
R esult s
Patient Characteristics
In the UNCOVER-1 trial, the mean age of the 
patients was 46 years, the mean weight was 92 kg, 
and the mean duration of psoriasis was 20 years. 
Two thirds of the patients were men. The mean 
body-surface-area involvement was greater than 
25%, and the mean PASI was approximately 20. 
Approximately 40% of the patients in the 
 UNCOVER-1 trial had received prior biologic ther-
apy, as compared with 24% in the UNCOVER-2 
trial and 16% in the UNCOVER-3 trial, probably 
because the UNCOVER-2 and UNCOVER-3 trials 
excluded patients who had prior use of etaner-
cept (Table 1).9
Efficacy
Induction Period (UNCOVER-1)
During the induction period in the UNCOVER-1 
trial, all primary and major secondary end 
points were met, with significantly greater im-
provements with both ixekizumab regimens than 
with placebo (Fig. 1). For all efficacy end points, 
the rates of response were higher in the 2-wk 
dosing group than in the 4-wk dosing group. 
Among the patients in the 2-wk dosing group, 
89.1% had a PASI 75 response, 70.9% had a PASI 
90 response, and 35.3% had a PASI 100 response 
at week 12 (Fig. 1). The results of the analyses of 
efficacy during the induction period were con-
sistent in the three UNCOVER trials (Fig. S4 and 
Table S2 in the Supplementary Appendix).9
Long-Term Extension Period (UNCOVER-3)
The high rates of response observed during the 
induction period were generally maintained during 
the long-term extension period in UNCOVER-3 
(Fig. 2). Most patients had maintained or attained 
near-complete resolution (PASI 90) or complete 
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resolution (PASI 100) of psoriasis plaques through 
week 60.
 Randomized Withdrawal Period (UNCOVER-1 and 
UNCOVER-2)
Among the patients who had an sPGA score of 
0 or 1 at week 12 and entered the randomized 
withdrawal periods in the UNCOVER-1 and 
UNCOVER-2 trials, 73.8% of the patients who 
were randomly reassigned to ixekizumab every 
4 weeks maintained an sPGA score of 0 or 1 at 
week 60; the corresponding rates for those ran-
domly reassigned to ixekizumab every 12 weeks 
or to placebo were 39.0% and 7.0%, respectively. 
When the patients were analyzed separately 
 according to the ixekizumab regimen during 
the induction period, an sPGA score of 0 or 1 
through week 60 was consistently maintained by 
78.3% of the patients in the 2-wk dosing group 
who went on to receive the every-4-week regi-
men in the randomized withdrawal period and 
by 68.7% of those in the 4-wk dosing group who 
Figure 1. Response to Ixekizumab During the Induction Period in the UNCOVER-1 Trial.
The induction period lasted for 12 weeks. The patients in the two active-treatment groups received a starting dose 
of 160 mg of ixekizumab followed by 80 mg of ixekizumab every 2 weeks (433 patients) or 80 mg of ixekizumab every 
4 weeks (432 patients); a total of 431 patients received placebo. Panel A shows the percentage of patients with a 
static Physician’s Global Assessment (sPGA) score of 0 or 1. Scores on the sPGA range from 0 (clear) to 5 (very 
 severe); a score of 3 indicates moderate disease. Panel B shows the percentage of patients with a 75% or greater 
 reduction from baseline in the Psoriasis Area and Severity Index (PASI) (PASI 75). The overall score on the PASI 
ranges from 0 (clear skin) to 72 (worst possible psoriasis); a score of 12 indicates moderate disease. Panel C shows 
the percentage of patients with 90% or greater reduction from baseline in PASI (PASI 90), and Panel D shows the 
percentage of patients with 100% reduction from baseline in PASI (PASI 100). P values were calculated with the use 
of a logistic-regression model unless the placebo value was equal to zero, in which case a Fisher’s exact test was 
used. Missing values were imputed as nonresponse.
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continued to receive the every-4-week regimen in 
the randomized withdrawal period; none of these 
patients had an observed exacerbation of psoria-
sis that resulted in an sPGA score of 3 or higher 
at any point between week 12 and week 60 (Fig. 
3A). Similarly, high rates were also maintained 
or attained between weeks 12 and 60 for other 
measures of high-level responses (PASI 75 [Fig. 
3B] and PASI 90 and PASI 100 [Fig. S5 in the 
Supplementary Appendix]).
Safety in the Pooled Data Set
During the 12-week induction period in all the 
UNCOVER trials, the patients who received ei-
ther regimen of ixekizumab had a higher rate of 
adverse events during this treatment period than 
did the patients who received placebo (Table 2). 
Among the patients who received ixekizumab 
during the induction period, the most common 
adverse events that occurred during the treat-
ment period included nasopharyngitis, upper re-
spiratory tract infection, injection-site reaction, 
injection-site erythema, and headache; among 
the patients who received placebo during the 
induction period, the most common adverse 
events during the induction period included na-
sopharyngitis, upper respiratory tract infection, 
psoriasis, headache, and pruritus (Table 2, and 
Table S3 in the Supplementary Appendix). The 
exposure-adjusted incidence rates of at least one 
serious adverse event and of discontinuation of 
the study regimen because of an adverse event 
were similar in the patients who received ixeki-
zumab and those who received placebo. The 
most common serious adverse event during 
weeks 0 to 12 among the patients who received 
ixekizumab was cellulitis, which occurred in 
3 patients; no serious adverse event was reported 
more than once among the patients who re-
ceived placebo. The integrated safety data set 
included pooled data from 3736 patients, account-
ing for 3458 patient-years of exposure to ixeki-
zumab. Nasopharyngitis remained the most 
common adverse event that occurred during the 
treatment period, from week 0 through week 60.
During the induction period, oral candidiasis 
occurred significantly more frequently in the 
2-wk dosing group than in the placebo group 
and occurred at a higher frequency in the 2-wk 
dosing group than in the 4-wk dosing group 
(Table 2, and Fig. S6 in the Supplementary Ap-
pendix). The exposure-adjusted incidence rate of 
candidal infections during weeks 0 through 60 
was similar to the rate during weeks 0 to 12. No 
candidal infection met the criteria for a serious 
adverse event, but in the UNCOVER-2 trial, one 
patient reported severe candidal otitis externa 
during the induction period and two patients 
reported severe oral candidiasis during weeks 12 
through 60.
Incidences of neutropenia of grades 1 and 2 
were more common among the patients who 
received ixekizumab than among the patients 
who received placebo during the induction period. 
Two patients who received ixekizumab and one 
Figure 2. Maintenance of Response to Ixekizumab during Weeks 0 through 
60 (UNCOVER-3).
Shown is the maintenance of response to ixekizumab, at a dose of 80 mg, 
during the long-term extension period (weeks 12 through 60) among the 
385 patients who had received ixekizumab every 2 weeks during the induc-
tion period (Panel A) and the 386 patients who had received ixekizumab 
every 4 weeks during the induction period (Panel B). The responses that 
were measured were an sPGA score of 0 or 1, PASI 75, PASI 90, and PASI 
100. Missing values were imputed as nonresponse.
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patient who received placebo had neutropenia of 
grade 3, and one patient who received ixeki-
zumab had neutropenia of grade 4 (Table 2). 
Overall, among all the patients who were ex-
posed to ixekizumab during weeks 0 through 
60, eight had neutropenia of grade 3 and two 
had neutropenia of grade 4.
The exposure-adjusted incidence rates of ma-
jor adverse cardiovascular and cerebrovascular 
events during the induction period were similar 
in the placebo group and the 4-wk dosing group 
(0.6 and 0.8, respectively); no patients in the 
2-wk dosing group had a major adverse cardio-
vascular or cerebrovascular event before week 12 
(Table 2, and Fig. S6 in the Supplementary Ap-
pendix). During weeks 12 through 60, two pa-
tients in the 2-wk dosing group who were ran-
domly reassigned to receive ixekizumab every 
4 weeks during the randomized withdrawal pe-
riod died from vascular causes: one patient had 
a myocardial infarction and the other had an 
ischemic stroke.
Among all patients who were treated with 
ixekizumab during the combined treatment pe-
riod (weeks 0 through 60), ulcerative colitis was 
reported in seven patients and Crohn’s disease 
was reported in four patients. Three patients 
who were randomly reassigned to placebo dur-
ing the randomized withdrawal period also re-
ported Crohn’s disease after 23, 70, and 134 days 
of receiving placebo (Table 2, and Fig. S6 in the 
Supplementary Appendix).
During the induction period, no significant 
differences were observed between the placebo 
group and either ixekizumab group or between 
the 2-wk dosing group and the 4-wk dosing 
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Figure 3. Consistency of Response during Maintenance 
Weeks 12 through 60 among Patients Who Had  
an sPGA 0 or 1 Response at Week 12 (UNCOVER-1  
and UNCOVER-2).
Patients who had an sPGA score of 0 or 1 at the end of 
the induction period (week 12) of the UNCOVER-1 and 
UNCOVER-2 trials were randomly reassigned to receive 
80 mg of ixekizumab every 4 weeks, 80 mg of ixekizu-
mab every 12 weeks, or placebo. Shown are the percent-
ages of patients who had an sPGA score of 0 or 1 at week 
12 in the pooled UNCOVER-1 and UNCOVER-2 trials, 
who maintained or attained an sPGA score of 0 or 1 
(Panel A) and who maintained or attained a PASI 75 
response (Panel B) during the randomized withdrawal 
period (weeks 12 through 60). Patients who had an sPGA 
score of 0 or 1 at the end of the induction period were 
randomly reassigned for the randomized withdrawal 
period to receive 80 mg of ixekizumab every 4 weeks, 
80 mg of ixekizumab every 12 weeks, or placebo. Miss-
ing values were imputed as nonresponse. The percent-
age of patients who had a consistent response to ixeki-
zumab through week 60 (those who maintained an sPGA 
score of 0 or 1 or a PASI 75 response) was significantly 
higher in the group that continued to receive ixekizumab 
during weeks 12 through 60 than in the group that re-
ceived placebo during weeks 12 through 60 (P<0.001 
for all comparisons). This analysis excludes subsequent 
results for patients who had an sPGA score of 3 or high-
er at any visit but may have subsequently regained re-
sponse while continuing to receive ixekizumab every  
4 weeks.
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group with respect to the exposure-adjusted in-
cidence rates of nonmelanoma skin cancer and 
cancers other than nonmelanoma skin cancers. 
The rates remained stable during weeks 0 through 
60 (Table 2, and Fig. S6 in the Supplementary 
Appendix).
Antidrug antibodies against ixekizumab de-
veloped in 103 of 1150 patients (9.0%) in the 
2-wk dosing group in the three UNCOVER trials 
during the induction period; 19 patients (1.7%) 
had high titers of antidrug antibodies (≥1:1280), 
accompanied by a lower clinical response than 
that of patients who had no or low-to-moderate 
titers of antidrug antibodies (Fig. S7A in the 
Supplementary Appendix). The patients in the 
2-wk dosing group who had a response at week 
12 and were randomly reassigned to receive ixeki-
zumab every 4 weeks during weeks 12 through 
60 did not have high titers of antidrug antibod-
ies and maintained high-level clinical responses, 
with no significant differences among the pa-
tients with no, low, or moderate titers (Fig. S7B 
in the Supplementary Appendix).
Discussion
Neutralization of IL-17A with ixekizumab was 
effective in the treatment of moderate-to-severe 
plaque psoriasis in three phase 3 trials involving 
3736 patients; ixekizumab was superior to pla-
cebo with respect to all primary and major sec-
ondary end points. In addition, 34 to 37% of the 
patients who received treatment with ixekizu-
mab had complete resolution (PASI 100 or sPGA 
score of 0) of their psoriasis plaques at week 12 
(UNCOVER-1). The high levels of clinical re-
sponse were maintained with continued expo-
sure to ixekizumab every 4 weeks through week 
60, with at least 50% of patients maintaining or 
attaining complete resolution of their psoriasis 
(PASI 100). Among the patients in the 2-wk dos-
ing group and the 4-wk dosing group who had 
an sPGA score of 0 or 1 at week 12 and were 
randomly reassigned to receive ixekizumab every 
4 weeks during the randomized withdrawal pe-
riod, 78.3% and 68.7%, respectively, maintained 
an sPGA score of 0 or 1 through week 60, with 
no exacerbation of their disease that resulted in 
an sPGA score of 3 or higher at any visit. All 
patients with an sPGA score of 0 or 1 at week 12 
could continue topical therapies as approved in 
the protocol, including those who were ran-
domly reassigned to ixekizumab every 12 weeks 
or to placebo; still, the majority of patients who 
were randomly reassigned to ixekizumab every 
12 weeks or to placebo did not maintain an 
sPGA score of 0 or 1 through week 60. Patients 
who had an sPGA score of 3 or higher at any 
visit began treatment with ixekizumab every 
4 weeks at that visit and may have subsequently 
regained a response during the course of the 
every-4-week regimen. The analyses in this re-
port excluded the subsequent results for those 
patients.
With more than 100 sites in 21 countries, the 
UNCOVER program represented a large, glob-
ally diverse population. Candidal infections oc-
curred more frequently among the patients treat-
ed with ixekizumab than among those who 
received placebo, a finding that is consistent 
with the role of IL-17A in the mucocutaneous 
defense against fungal infections.15
Although low serum levels of IL-17 have been 
associated with repeat myocardial infarctions 
and may affect atherosclerotic plaque stability,16 
the role of neutralizing IL-17 in cardiovascular 
disease is complex and should be defined by 
careful monitoring and long-term studies involv-
ing large numbers of patients.17 During the 12-
week induction periods in these three trials, the 
risk of adverse cardiovascular events did not 
differ between the patients who received placebo 
and those who received ixekizumab. Among all 
patients in the UNCOVER trials who received 
ixekizumab during weeks 0 through 60, there 
were two confirmed deaths from vascular causes. 
The third death in the UNCOVER program was 
reported as being due to unknown causes (the 
patient had received ixekizumab every 4 weeks 
in both the induction and maintenance periods).
In the UNCOVER trials, 11 patients reported 
inflammatory bowel disease while receiving ix-
ekizumab, and 3 additional patients reported 
inflammatory bowel disease while receiving pla-
cebo during the randomized withdrawal period 
after they had received ixekizumab during the 
induction period. The results from the UNCOVER 
trials suggest that further evaluation is needed 
to understand the relationship between IL-17A 
inhibitors and inflammatory bowel disease.
Ixekizumab provided high levels of clinical 
response at week 12 and through week 60. How-
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Adverse Event Weeks 0–12 Weeks 0–60
Placebo 
(N = 791)
Ixekizumab Every 4 wk 
(N = 1161)
Ixekizumab Every 2 wk 
(N =1167)
All Patients with 
Ixekizumab Exposure 
(N = 3736)
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
Any adverse event† 370 (46.8) 205.5 683 (58.8) 256.8 681 (58.4) 253.6 3021 (80.9) 87.4
Serious adverse event 12 (1.5) 6.7 26 (2.2) 9.8 20 (1.7) 7.4 250 (6.7) 7.2
Discontinuation of study 
 regimen because of 
an adverse event
9 (1.1) 5.0 24 (2.1) 9.0 25 (2.1) 9.3 165 (4.4) 4.8
Death 0 0.0 0 0.0 0 0.0 3 (0.1) 0.1
Common adverse events‡
Nasopharyngitis 69 (8.7) 38.3 104 (9.0) 39.1 111 (9.5) 41.3 733 (19.6) 21.2
Upper respiratory tract 
 infection
28 (3.5) 15.6 45 (3.9) 16.9 51 (4.4) 19.0 372 (10.0) 10.8
Injection-site reaction 9 (1.1) 5.0 89 (7.7) 33.5 117 (10.0) 43.6 387 (10.4) 11.2
Arthralgia 17 (2.1) 9.4 22 (1.9) 8.3 29 (2.5) 10.8 196 (5.2) 5.7
Headache 23 (2.9) 12.8 50 (4.3) 18.8 51 (4.4) 19.0 243 (6.5) 7.0
Selected adverse events of 
 special interest
Infection or infestation 181 (22.9) 100.5 318 (27.4) 119.6 315 (27.0) 117.3 2064 (55.2) 59.7
Candidal§ 4 (0.5) 2.2 7 (0.6) 2.6 16 (1.4) 6.0 128 (3.4) 3.7
Oral 0 0.0 2 (0.2) 0.8 9 (0.8) 3.4 63 (1.7) 1.8
Vulvovaginal¶ 3 (1.3) 1.7 5 (1.3) 1.9 3 (0.7) 1.1 40 (3.3) 3.6
Skin 1 (0.1) 0.6 0 0.0 2 (0.2) 0.7 20 (0.5) 0.6
Esophageal 0 0.0 0 0.0 1 (0.1) 0.4 2 (0.1) 0.1
Nail 0 0.0 0 0.0 0 0.0 1 (<0.1) 0.0
Unspecified 0 0.0 0 0.0 0 0.0 9 (0.2) 0.3
Major adverse cardiovascular 
and cerebrovascular 
events‖
1 (0.1) 0.6 2 (0.2) 0.8 0 0.0 23 (0.6) 0.7
Crohn’s disease 0 0.0 1 (0.1) 0.4 1 (0.1) 0.4 4 (0.1) 0.1
Ulcerative colitis 0 0.0 0 0.0 2 (0.2) 0.7 7 (0.2) 0.2
Cancer, excluding nonmela-
noma skin cancer
1 (0.1) 0.6 2 (0.2) 0.8 1 (0.1) 0.4 14 (0.4) 0.4
Nonmelanoma skin cancer 1 (0.1) 0.6 1 (0.1) 0.4 2 (0.2) 0.7 20 (0.5) 0.6
Selected serious adverse events 
of special interest
Infection 3 (0.4) 1.7 8 (0.7) 3.0 5 (0.4) 1.9 51 (1.4) 1.5
Major adverse cardiovascular 
and cerebrovascular 
events‖
1 (0.1) 0.6 2 (0.2) 0.8 0 0.0 22 (0.6) 0.6
Crohn’s disease 0 0.0 1 (0.1) 0.4 1 (0.1) 0.4 3 (0.1) 0.1
Table 2. Adverse Events during the Induction Periods and the Total Ixekizumab Exposure in the Three UNCOVER Trials.*
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ever, as with any treatment, the benefits need to 
be weighed against the adverse events, and the 
safety profile of longer-term treatment with ixeki-
zumab should be examined.
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Adverse Event Weeks 0–12 Weeks 0–60
Placebo 
(N = 791)
Ixekizumab Every 4 wk 
(N = 1161)
Ixekizumab Every 2 wk 
(N =1167)
All Patients with 
Ixekizumab Exposure 
(N = 3736)
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
no. of 
patients  
(%)
incidence 
rate/100 
patient-yr
Ulcerative colitis 0 0.0 0 0.0 0 0.0 1 (<0.1) 0.0
Cancer, excluding nonmela-
noma skin cancers
1 (0.1) 0.6 1 (0.1) 0.4 0 0.0 10 (0.3) 0.3
Nonmelanoma skin cancer 0 0.0 0 0.0 0 0.0 2 (0.1) 0.1
Other serious adverse 
event**
9 (1.1) 5.0 16 (1.4) 6.0 15 (1.3) 5.6 179 (4.8) 5.2
Neutropenia††
Grade 1 23 (2.9) – 76 (6.6) – 81 (7.0) – 321 (8.6) –
Grade 2 2 (0.3) – 22 (1.9) – 25 (2.1) – 97 (2.6) –
Grade 3 1 (0.1) – 0 – 2 (0.2) – 8 (0.2) –
Grade 4 0 – 1 (0.1) – 0 – 2 (0.1)
*  The placebo group represented 180.0 patient-years; the group that received ixekizumab every 4 weeks, 265.9 patient-years; the group that 
received ixekizumab every 2 weeks, 268.6 patient-years; and the combined groups with ixekizumab exposure, 3458.4 patient-years.
†  Adverse events included here are those that appeared or worsened during the treatment periods.
‡  Common adverse events occurring during treatment were defined as those that had an incidence rate of at least 5% among all the patients 
with ixekizumab exposure and occurred in a greater number of patients who received ixekizumab than patients who received placebo dur-
ing the induction period.
§  A list of specific terms included in each category of candidal infection is provided in the Methods section in the Supplementary Appendix.
¶  Because this event was sex-specific for females, the denominator was adjusted to 232 for the placebo group, 374 for the group that re-
ceived ixekizumab every 4 weeks, 401 for the group that received ixekizumab every 2 weeks, and 1207 for all the patients with ixekizumab 
 exposure.
‖  Major adverse cardiovascular and cerebrovascular events were included only if they were confirmed after adjudication.
**  A list of other serious adverse events is provided in Table S4 in the Supplementary Appendix.
††  The number of patients with a least one postbaseline value for neutrophil level was 787 in the placebo group, 1152 in the group that received 
ixekizumab every 4 weeks, 1163 in the group that received ixekizumab every 2 weeks, and 3716 among all the patients with ixekizumab 
 exposure. Neutropenia data include patients with postbaseline neutrophil counts that worsened from a normal level or from the grade  
at baseline. Neutropenia of grade 1 was defined as an absolute neutrophil count of 1500 to less than 2000 per cubic millimeter (from a 
normal level at baseline); grade 2, as a count of 1000 to less than 1500 per cubic millimeter (from a normal level or grade 1 at baseline); 
grade 3, as a count of 500 to less than 1000 per cubic milliliter (from a normal level or grade 1 or 2 at baseline); and grade 4, as a count  
of less than 500 per cubic millimeter (from a normal level or grade 1, 2, or 3 at baseline).
Table 2. (Continued.)
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